WASHINGTON, April 9 (Reuters) - Johnson & Johnson’s (JNJ.N: Quote, Profile , Research) bladder drug Ditropan needs stronger cautions about the risk of hallucination and similar problems in children and older patients, U.S. Food and Drug Administration staff said in documents released on Monday.
